← All trials
NCT05259189
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2021
- Primary completion
- May 23, 2022
- Completion date
- May 23, 2022
- First posted
- Feb 28, 2022
- Last posted
- Jul 20, 2022
- Enrollment
- 52
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NovaRock Biotherapeutics, LtdLead sponsor
- Soochow UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.